Dalton Transactions · 2015 · 28 citations · 36 references
MedicineMedicinal ChemistryPharmacologyApoptosisCancer PharmacologyChemotherapyAntioxidant DefenseApoptosis PharmacologyCytotoxic ChemotherapyGlutathione MetabolismHypoxia AdaptationReactive Oxygen SpeciesApoptotic Resistance In HypoxiaCell Cycle DynamicsCell Cycle InhibitionCellular Antioxidant DefenseG2/m TransitionGlutathione In Drug ResistanceGlutathione Redox SystemHypoxia-mediated Resistance
A slow hydrolyzing imidazole-based Ru(II)-arene complex [(L)Ru(II)(η(6)-p-cym)(Cl)](PF6) (1) with excellent stability in the extracellular chloride concentration shows better activity under hypoxia and strong resistance to glutathione (GSH) in vitro under hypoxic conditions. 1 arrests the cell cycle in sub G1 and G2/M phases and leads to apoptosis.
36
AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer
Sarah L. Anzick, Juha Kononen, Robert L. Walker et al. · Science · 1997 · 1.7K citations
Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate
Ferdia A. Gallagher, Mikko I. Kettunen, Sam E. Day et al. · Nature · 2008 · 846 citations
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
C. Scolaro, Alberta Bergamo, L. Brescacin et al. · Journal of Medicinal Chemistry · 2005 · 774 citations · Full text
Ruthenium metallopharmaceuticals
Michael J. Clarke · Coordination Chemistry Reviews · 2003 · 675 citations
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Robert Trondl, Petra Heffeter, Christian R. Kowol et al. · Chemical Science · 2014 · 659 citations · Full text
Medicine, Oncology, Pharmacology +14